http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022144810-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f4c98ffd9287e4a6257797f3d4a9e57 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2250-0067 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-915 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-915 |
| filingDate | 2021-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5deab90a7ed2c129fbba41e9a67df96b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_835b3401c054f64f1f934ffbd8e0c217 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edd6a0a6af70f12fb8aeff69affbfd16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b31ecf12e3cb4d7ad20453f8f9e0fb8d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ecd86c6ebc96e0602aa032a63de679e |
| publicationDate | 2022-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022144810-A1 |
| titleOfInvention | Drug eluting stent |
| abstract | The present disclosure relates to drug eluting stents (DES), methods of making, using, and verifying long-term stability of the DES, and methods for predicting long term stent efficacy and patient safety after implantation of a DES. In one embodiment, a DES may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition, or in alternative, the drug-containing layer may be configured to enable an instantaneous drug release which is maximum at a time where smooth muscle cells should have their maximum proliferation, to be essentially zero ca. 30 days after implantation, and to significantly dissolve/dissipate/disappear between 45 days and 90 days after stent implantation. Stents of the present disclosure focus on suppressing smooth muscle cells' over- proliferation, without hindering their normal growth, which may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115671407-A |
| priorityDate | 2020-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 654.